Viewing data from:

TRYNGOLZA (AUTOINJECTOR)

NDA

OLEZARSEN SODIUM | N218614 | IONIS PHARMACEUTICALS INC

1 strength6 unique patents1 unique exclusivity

Patent Timeline

6 unique patents, 1 exclusivity by expiration date

Active (6)TodayExclusivity

2027

2028

2029

2030

2031

2032

2033

2034

Today

May. 1, 2034

Apr. 27, 2032

May. 1, 2034

May. 1, 2034

Feb. 14, 2034

May. 1, 2034

ODE-515

Dec. 19, 2031

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

Approval Letters

2 letters from Drugs@FDA

Date	Submission	Document
Jun 26, 2026	SUPPL -4	View Letter (PDF)
Dec 20, 2024	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — EQ 80MG BASE/0.8ML (EQ 80MG BASE/0.8ML)

RLD

6 patents1 exclusivity▴

SOLUTION;SUBCUTANEOUS | Approved: Dec 19, 2024

Patents (6)

Patent #	Expiration	PED	Drug Substance	Drug Product	Use Code	Delist
9127276	May 1, 2034	—	Yes	—	—	—
9157082	Apr 27, 2032	—	—	—		—
9163239	May 1, 2034	—	Yes	—	—	—
9181549	May 1, 2034	—	Yes	—	—	—
9593333	Feb 14, 2034	—	—	—		—
12509684	May 1, 2034	—	—	—		—

Exclusivities (1)

Code	Date	Status
ODE-515	Dec 19, 2031	Active